19 Biogen Idec SWOT analysis 93 Figure 8

Top reasons to order your copy today Identify the market dynamics of the global specialty pharma industry over the2006-07 period, understand the potential benefits of emerging business modelsand identify the latest industrial trends across the UK, Japan, France, Germany,Italy, Spain and the US. Evaluate the performance and strategies of the top 10 players in the globalspecialty pharma market with this reports examination of the geographic andtherapeutic focus and currently marketed product portfolios of Servier, Gilead,Forest, Shire, Biogen Idec, Cephalon, Sepracor, Lundbeck, Endo Pharma and CSL. Measure the progress of leading specialty pharma companies outside of the topten by anlaysing the portfolios and therapeutic/geographic focus of Covidien,Allergan, ONO, Genzyme, Gruenenthal, Warner Chilcott, Ferring, Stiefel Labs,Bracco and Leo Pharma. Key issues examined in this report Genericization of specialty products. Specialty pharma products with orphandrug status become vulnerable to genericization once this status has expired.Biogenerics are increasing as a result of favourable EU legislation Cannibalization of product sales.

Thiscannibalization has resulted in a shortening of individual product lifecycles. Lack of incentives in Europe. Pricing and reimbursement pressures in Europehave created greater boundaries to innovation, leading to fewer undervaluedlate-stage products. As a result, traditional specialty companies are likely toface future difficulties in this region CNS treatments dominate the specialty sector. CNS is the largest therapeuticarea for the leading specialty pharma companies, with half of the top tencompanies focused on CNS and neurology treatments. Your questions answered How fast is the global market for specialty pharmaceutical treatmentsexpanding What are the trends in the global specialty pharmaceutical market Who are the top 10 players in the industry and how much of the market do theycontrol Which growth strategies have proven most effective Which business models have been adopted by leading companies to gaincompetitive advantage and enhance market share What are the strengths, weaknesses, opportunties and threats facing each ofthe top 10 players Where are the most exciting growth opportunities for leading specialtypharmaceutical companies Table of Contents The top ten specialty pharmaceutical companies Executive Summary 14 Industry overview 14 Servier 15 Forest 15 Gilead 16 Shire 17 Biogen Idec 17 Cephalon 18 Sepracor 19 Lundbeck 19 Endo Pharmaceuticals 20 CSL 21 Chapter 1 Introduction 24 Scope of the report 24 Methodology 24 Chapter 2 Industry overview 28 Summary 28 Introduction 29 Different models of the specialty pharmaceutical industry 29 Product licensing players 30 Niche therapeutic area concentrators 30 De-prioritized product adopters 31 Drug delivery experts going up the value chain 31 Branded genericization experts 32 Market size and growth rate 33 Global positioning of the top 10 specialty pharmaceutical companies 34 Therapeutic focus of the top 10 34 Geographic focus of the top 10 36 Trends in the specialty pharmaceutical industry 38 Product life extension through label expansion 38 Genericization of specialty pharmaceutical products 39 Evolving specialty pharmaceutical industry in Japan and China 40 Japanese market 41 Chinese market 41 Drug delivery companies transitioning to specialty pharma companies 42 Chapter 3 Servier 44 Summary 44 Company overview 45 Geographic focus 46 Marketed products 47 Major therapeutic focus 48 Growth strategies 49 Investment in R&D capabilities 49 Acquisitions and divestments 49 SWOT analysis 50 Strengths 50 Strong in-house R&D capabilities 50 Dominant market position in Russia 51 Weaknesses 51 Dependence on low growth therapy areas 51 Opportunities 51 Boosting R&D efforts through collaboration 51 Threats 52 Tough operating conditions in France 52 Chapter 4 Forest 54 Summary 54 Company overview 55 Geographic focus 55 Marketed products 56 Major therapeutic focus 57 Growth strategies 57 Product acquisitions 57 Acquisitions/divestments 58 SWOT analysis 59 Strengths 59 Strong balance sheet 59 Strong selling and marketing capabilities 60 Weaknesses 60 Highly dependent on one blockbuster drug-Lexapro 60 Opportunities 60 Growing hospital-acquired infections (HAI) drug market 60 Threats 61 Sluggish antidepressant market 61 Chapter 5 Gilead 64 Summary 64 Company overview 65 Geographic focus 66 Marketed products 67 Major therapeutic focus 67 Growth strategies 67 Maintaining leadership position in the HIV/AIDS treatment 67 Expanding product portfolio in new therapy areas 68 Gaining traction in developing economies 69 Acquisitions and divestments 69 SWOT analysis 70 Strengths 70 Strong customer base for antiretroviral therapy 70 Strong presence in antiviral market 71 Weaknesses 71 Dependence on limited number of wholesalers in the US 71 Opportunities 72 Expanding treatments for chronic hepatitis 72 Agreement with Navitas Assets for Pulmonary Arterial Hypertension (PAH) 72 Robust product pipeline in Phase II and Phase III clinical trials 72 Threats 73 Intense competition in crowded market segments 73 New product launches may cannibalize existing product sales 73 Chapter 6 Shire 76 Summary 76 Company overview 77 Geographic focus 78 Marketed products 79 Major therapeutic focus 80 Growth strategies 80 Focus outside the US 80 Focus on R&D in core therapeutic areas 81 Acquisitions and divestments 81 SWOT analysis 82 Strengths 82 Strong position in the US ADHD market 82 Weaknesses 83 Increase in SG&A expenses 83 Opportunities 83 Strong development pipeline 83 Expansion into Europe 84 Ability to Capitalize on the emerging adult ADHD market 84 Threats 84 Declining royalties with increasing competition 84 Chapter 7 Biogen Idec 88 Summary 88 Company overview 89 Geographic focus 90 Marketed products 91 Major therapeutic focus 91 Growth strategies 91 Expanding footprint in markets outside the US 91 Acquisitions and divestments 92 SWOT analysis 93 Strengths 93 Significant presence in immune system and oncology therapeutic areas 93 Weaknesses 94 Substantial dependence on Avonex revenues 94 Opportunities 94 Robust product development pipeline 94 Threats 94 Increasing threat to Avonex in MS market 94 Arbitration with partner Genentech over Rituxan 95 Chapter 8 Cephalon 98 Summary 98 Company overview 99 Geographic focus 100 Marketed products 101 Major therapeutic focus 102 Growth strategies 102 Focus on growing oncology business and expanding beyond Europe 102 Acquisitions and divestments 103 SWOT analysis 104 Strengths 104 Strong presence in CNS with Provigil leading in the forefront 104 Strong pain management franchise 105 Weaknesses 105 Positioned in low growth therapeutic area 105 Opportunities 106 Strong late-stage product pipeline 106 Threats 106 Heavy focus on the US market 106 Chapter 9 Sepracor 110 Summary 110 Company overview 111 Geographic focus 111 Marketed products 112 Major therapeutic focus 113 Growth strategies 113 Realignment and expansion of sales force to enhance traction in target markets 113 Expansion beyond the US market 114 Acquisitions and divestments 114 SWOT analysis 115 Strengths 115 Strong presence in insomnia drug market 115 Focused promotion in insomnia drug market 116 Weaknesses 116 Presence in low growth therapy areas 116 Opportunities 116 Successful licensing agreements 116 Threats 117 Single-isomers susceptible to patent challenges 117 Chapter 10 Lundbeck 120 Summary 120 Company overview 121 Geographic focus 122 Marketed products 123 Major therapeutic focus 123 Growth strategies 123 Establish commercial presence in Japan and the US 123 Acquisitions and divestments 124 SWOT analysis 125 Strengths 125 Strong position in the CNS market 125 Weaknesses 126 No commercial presence in the worlds largest pharmaceutical markets 126 Opportunities 126 Broad product pipeline 126 Threats 127 R&D setbacks 127 Chapter 11 Endo Pharmaceuticals 130 Summary 130 Company overview 131 Geographic focus 131 Marketed products 132 Major therapeutic focus 132 Growth strategies 132 Focused marketing and promotional efforts for established brands 132 Enhancing product line through in-licensing complementary products, compounds and technologies 133 Acquisitions and divestments 133 SWOT analysis 134 Strengths 134 Robust portfolio of branded products 134 Weaknesses 135 Over reliance on two key customers 135 Opportunities 135 Expansion of product portfolio through licensing agreement 135 Threats 136 Generic competition 136 Chapter 12 CSL 138 Summary 138 Company overview 139 Geographic focus 140 Marketed products 141 Major therapeutic focus 142 Growth strategies 142 Invest in new product development 142 Acquisitions and divestments 143 SWOT analysis 144 Strengths 144 Strong market position in plasma therapeutics 144 Weaknesses 145 Product recalls 145 Opportunities 145 Proposed acquisition of Talecris 145 Threats 145 Impact of AUSFTA 145 Chapter 13 11 to 20 Companies 148 Covidien 148 Company overview 148 Geographic focus 149 Marketed products 150 Major therapeutic focus 151 Allergan 152 Company overview 152 Geographic focus 153 Marketed products 154 Major therapeutic focus 155 ONO 156 Company overview 156 Marketed products 157 Major therapeutic focus 158 Genzyme 159 Company overview 159 Geographic focus 160 Marketed products 161 Major therapeutic focus 162 Gruenenthal 163 Company overview 163 Geographic focus 163 Marketed products 165 Major therapeutic focus 166 Warner Chilcott 167 Company overview 167 Geographic focus 167 Marketed products 168 Major therapeutic focus 169 Ferring 170 Company overview 170 Geographic focus 171 Marketed products 172 Major therapeutic focus 173 Stiefel Labs 174 Company overview 174 Geographic focus 175 Marketed products 176 Major therapeutic focus 177 Bracco 178 Company overview 178 Geographic focus 179 Marketed products 180 Major therapeutic focus 181 Leo Pharma 182 Company overview 182 Geographic focus 183 Marketed products 184 Major therapeutic focus 185 Chapter 14 Appendix 188 Glossary 188 Index 189 List of Figures Figure 2.1: Niche therapeutic area concentrators business model 30 Figure 2.2: De-prioritized product adopters business model 31 Figure 2.3: Drug delivery experts business model 32 Figure 2.4: Branded genericization experts business model 32 Figure 2.5: Top 10 specialty pharmaceutical companies global market share (),2007 34 Figure 2.6: Geographic focus of the top 10 companies in the US/5EU, 2007 36 Figure 2.7: Trends in the specialty pharmaceuticals industry 38 Figure 3.8: Serviers geographic focus, 2006-07 46 Figure 3.9: Serviers therapeutic focus, 2007 48 Figure 3.10: Servier SWOT analysis 50 Figure 4.11: Forests therapeutic focus, 2007 57 Figure 4.12: Forest SWOT analysis 59 Figure 5.13: Gileads geographic focus, 2006-07 66 Figure 5.14: Gilead SWOT analysis 70 Figure 6.15: Shires geographic focus, 2006-07 78 Figure 6.16: Shires therapeutic focus, 2007 80 Figure 6.17: Shire SWOT analysis 82 Figure 7.18: Biogen Idecs geographic focus, 2006-07 90 Figure 7.19: Biogen Idec SWOT analysis 93 Figure 8.20: Cephalons geographic focus, 2006-07 100 Figure 8.21: Cephalons therapeutic focus, 2007 102 Figure 8.22: Cephalon SWOT analysis 104 Figure 9.23: Sepracors therapeutic focus, 2007 113 Figure 9.24: Sepracor SWOT analysis 115 Figure 10.25: Lundbecks geographic focus, 2006-07 122 Figure 10.26: Lundbeck SWOT analysis 125 Figure 11.27: Endo Pharm SWOT analysis 134 Figure 12.28: CSLs geographic focus, 2006-07 140 Figure 12.29: CSLs therapeutic focus, 2007 142 Figure 12.30: CSL SWOT analysis 144 Figure 13.31: Covidiens geographic focus, 2006-07 149 Figure 13.32: Covidiens therapeutic focus, 2007 151 Figure 13.33: Allergans geographic focus, 2006-07 153 Figure 13.34: Allergans therapeutic focus, 2007 155 Figure 13.35: ONOs therapeutic focus, 2007 158 Figure 13.36: Genzymes geographic focus, 2006-07 160 Figure 13.37: Genzymes therapeutic focus, 2007 162 Figure 13.38: Gruenenthals geographic focus, 2006-07 164 Figure 13.39: Gruenenthals therapeutic focus, 2007 166 Figure 13.40: Warner Chilcotts therapeutic focus, 2007 169 Figure 13.41: Ferrings geographic focus, 2006-07 171 Figure 13.42: Ferrings therapeutic focus, 2007 173 Figure 13.43: Stiefel Labs geographic focus, 2006-07 175 Figure 13.44: Stiefel Labs therapeutic focus, 2007 177 Figure 13.45: Braccos geographic focus, 2006-07 179 Figure 13.46: Braccos therapeutic focus, 2007 181 Figure 13.47: Leo Pharmas geographic focus, 2006-07 183 Figure 13.48: Leo Pharmas therapeutic focus, 2007 185 List of Tables Table 2.1: Largest therapy areas for the top 10 companies ($m), 2007 35 Table 2.2: Top 10 specialty pharmaceutical companies sales in the US/5EU ($m),2007 37 Table 2.3: Orphan biologics blockbuster with expired market exclusivity in theUS 40 Table 3.4: Servier snapshot 45 Table 3.5: Serviers top marketed products global sales ($m), 2007 47 Table 4.6: Forest snapshot 55 Table 4.7: Forests top marketed products global sales ($m), 2007 56 Table 5.8: Gilead snapshot 65 Table 5.9: Gileads top marketed products global sales ($m), 2007 67 Table 6.10: Shire snapshot 77 Table 6.11: Shires top marketed products global sales ($m), 2007 79 Table 7.12: Biogen Idec snapshot 89 Table 7.13: Biogen Idecs top marketed products global sales ($m), 2007 91 Table 8.14: Cephalon snapshot 99 Table 8.15: Cephalons top marketed products global sales ($m), 2007 101 Table 9.16: Sepracor snapshot 111 Table 9.17: Sepracors top marketed products global sales ($m), 2007 112 Table 10.18: Lundbeck snapshot 121 Table 10.19: Lundbecks top marketed products global sales ($m), 2007 123 Table 11.20: Endo Pharmaceuticals snapshot 131 Table 11.21: Endo Pharmaceuticals top marketed products global sales ($m), 2007132 Table 12.22: CSL snapshot 139 Table 12.23: CSLs top marketed products global sales ($m), 2007 141 Table 13.24: Covidien snapshot 148 Table 13.25: Covidiens top marketed products global sales ($m), 2007 150 Table 13.26: Allergan snapshot 152 Table 13.27: Allergans top marketed products global sales ($m), 2007 154 Table 13.28: ONO snapshot 156 Table 13.29: ONOs top marketed products global sales ($m), 2007 157 Table 13.30: Genzyme snapshot 159 Table 13.31: Genzymes top marketed products global sales ($m), 2007 161 Table 13.32: Gruenenthal snapshot 163 Table 13.33: Gruenenthals top marketed products global sales ($m), 2007 165 Table 13.34: Warner Chilcott snapshot 167 Table 13.35: Warner Chilcotts top marketed products global sales ($m), 2007 168Table 13.36: Ferring snapshot 170 Table 13.37: Ferrings top marketed products global sales ($m), 2007 172 Table 13.38: Stiefel Labs snapshot 174 Table 13.39: Stiefel Labs top marketed products global sales ($m), 2007 176 Table 13.40: Bracco snapshot 178 Table 13.41: Braccos top marketed products global sales ($m), 2007 180 Table 13.42: Leo Pharma snapshot 182 Table 13.43: Leo Pharmas top marketed products global sales ($m), 2007 184 To order this report:The Top Ten Specialty Pharmaceutical Companies: Positioning, performance andSWOT analyses http:// market research reports here!ReportlinkerNicolas: US: (805)-652-2626Intl: 1 805-652-2626 Copyright Business Wire 2009. After A completly awful start to  the season the hurricanes are 3-0-1 in the past four games, so this brings up the question are the Hurrcanes turning this season around  Here are some of the reasons.1.  Brandon SutterThis a player who was brought up from the Albany River Rats and has played in 11 games with 5 goals 3 assists 8 points and a 1.Is this the person that the Canes have been waiting for to turn the season around  It sure looks like it as he started his pro career on the fourth line and worked his way up to the first line.2. DefenseThe defense has gotten much better over the last four games including last night's game giving up only one goal.All this coming with their back-up back-up goalie Manny Legace. 3.

InjuriesEven with the injuries taking out their goalie back-up goalie and best player, the Hurricanes have battled back to their best stretch of the season.Even though the hurricanes are still doing better this is the rankings in the Southeast.1 Washington (31pts)2. Tampa Bay (25pts)3.Atlanta (23pts)4.Florida Panthers (22pts)5.Carolina (15pts)We hav a lot to do to catch back-up this is what needs to be done.1. 8 /PRNewswire-USNewswire/ Recent ground-breakingresearch that investigates gene sequences in living organisms offers a newunderstanding of biology and life in general. The relatively young field,called Genomics, has the potential for development of new medical treatmentsand biological sources of energy.(Logo: http://) On Tuesday, Jan. 13, NASA's Langley Research Center, Hampton, Va., is hostingtwo executives from Synthetic Genomics, Inc., a company dedicated todeveloping and commercializing genomic-driven solutions to address globalenergy and environmental challenges Dr. Aristides Patrinos, president of Synthetic Genomics, will speak to NASALangley employees on "Energy for the Greenhouse World" at 2 p.m in the ReidConference Center.

Craig Venterwill present a talk for the general public called "From Reading to Writing theGenetic Code" at 7:30 p.m at the Virginia Air & Space Center in downtownHampton. was founded in 2005 by Venter who was named one ofthe 100 most influential scientists of 2008 by Time magazine. His company isdeveloping new scientific processes to enable industry to design and testgenetic modifications. You will receive an e-mail asking you to visit a link to confirm theaction. To unsubscribe, send an e-mail message with the word "unsubscribe" in the subjectline.SOURCENASAEmily Outen of NASA, 1-757-864-7022, . Photo: John Kuntz/Cleveland Today, Brady Quinn threw for 304 yards and 4 touchdowns, the Browns amassed 439 total yards, they converted 10-of-19 third downs, converted 2-of-2 fourth downs, did not turn the ball over, controlled the ball for nearly 35 minutes, and the Browns jumped out to a 24-3 lead in the first quarter on the way to their second victory of the season. It sounds great, doesn't itThe only problem is the Browns didn't win, and that defense that I so greatly praised not six days ago is the main culprit.